Trial · NCT02284399
National Prevalence and Impact of Noninvasive Prenatal Testing
NCT02284399, Completed, Obstetrix Medical Group; results first posted 2019-06-19
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. National Prevalence and Impact of Noninvasive Prenatal Testing. Trials, record NCT02284399. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02284399
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- National Prevalence and Impact of Noninvasive Prenatal Testing
- NCT number
- NCT02284399
- Status
- Completed
- Enrollment
- 4,488 participants, actual
- Lead sponsor
- Obstetrix Medical Group
- Conditions
- Aneuploidy
- Interventions
- non-invasive prenatal testing
- First posted
- 2014-11-06
- Last updated
- 2019-06-19
- Results first posted
- 2019-06-19
Source ClinicalTrials.gov
Registered outcomes2
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Patient Undergoing IDTFK Before (Control) and After (Test) NIPT Testing Came to Market | 4 years | Total Number of patient undergoing invasive diagnostic testing for fetal karyotype (IDTFK) before (control group = Jan - July 2010) and after (test group=Jan 2012-June 2014) NIPT testing came to market |
| Secondary | Frequency of Positive Tests for Abnormal Karyotype Before and After the Adoption of NIPT Testing. | 4 years | Will determine if frequency of positive tests for abnormal karyotypes between the control period and the study period where different. |
Source ClinicalTrials.gov
Outcomes2
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Patient Undergoing IDTFK Before (Control) and After (Test) NIPT Testing Came to Market | 4 years | This was an observational study that looked to compare the number of patient who underwent IDTFK during Jan 2010-July 2010 (prior to the adoption of NIPT) with the number of patients who underwent IDTFK during Jan 2012-June 2014 (after the adoption of NIPT). | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Frequency of Positive Tests for Abnormal Karyotype Before and After the Adoption of NIPT Testing. | 4 years | The number of positive tests identified between the control and the test periods. | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group4
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Patient Undergoing IDTFK Before (Control) and After (Test) NIPT Testing Came to Market | IDTFK Group Pre-NIPT (January 2010-July 2010) | 1414 | Participants | ||
| Number of Patient Undergoing IDTFK Before (Control) and After (Test) NIPT Testing Came to Market | IDTFK Group Post NIPT - (January 2012-June 2014) | 3074 | Participants | ||
| Frequency of Positive Tests for Abnormal Karyotype Before and After the Adoption of NIPT Testing. | IDTFK Group Post NIPT - (January 2012-June 2014) | 454 | Participants | ||
| Frequency of Positive Tests for Abnormal Karyotype Before and After the Adoption of NIPT Testing. | IDTFK Group Pre-NIPT (January 2010-July 2010) | 104 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | IDTFK Group Pre-NIPT (January 2010-July 2010) | 1,414 | |
| Overall Study | STARTED | IDTFK Group Post NIPT - (January 2012-June 2014) | 3,074 | |
| Overall Study | COMPLETED | IDTFK Group Pre-NIPT (January 2010-July 2010) | 1,414 | |
| Overall Study | COMPLETED | IDTFK Group Post NIPT - (January 2012-June 2014) | 3,074 | |
| Overall Study | NOT COMPLETED | IDTFK Group Pre-NIPT (January 2010-July 2010) | 0 | |
| Overall Study | NOT COMPLETED | IDTFK Group Post NIPT - (January 2012-June 2014) | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | IDTFK Group Pre-NIPT (January 2010-July 2010) | 0 | 0 |
| Total, all-cause mortality | IDTFK Group Post NIPT - (January 2012-June 2014) | 0 | 0 |
| Total, other adverse events | IDTFK Group Pre-NIPT (January 2010-July 2010) | 0 | 0 |
| Total, other adverse events | IDTFK Group Post NIPT - (January 2012-June 2014) | 0 | 0 |
| Total, serious adverse events | IDTFK Group Pre-NIPT (January 2010-July 2010) | 0 | 0 |
| Total, serious adverse events | IDTFK Group Post NIPT - (January 2012-June 2014) | 0 | 0 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| IDTFK Group Pre-NIPT (January 2010-July 2010) vs IDTFK Group Post NIPT - (January 2012-June 2014): Number of Patient Undergoing IDTFK Before (Control) and After (Test) NIPT Testing Came to Market | Trial comparisons |
| IDTFK Group Post NIPT - (January 2012-June 2014) vs IDTFK Group Pre-NIPT (January 2010-July 2010): Frequency of Positive Tests for Abnormal Karyotype Before and After the Adoption of NIPT Testing. | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02284399
GET https://conductscience.org/api/trials/v1/NCT02284399/registered